Applied Therapeutics, Inc. Forecast, price target & analysts
Applied Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Applied Therapeutics, Inc. Classifications & Recommendation:
Applied Therapeutics, Inc. Price Target
| Target Price | $2.04 |
| Price | $0.12 |
| Potential |
1,667.76%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Applied Therapeutics, Inc. 2026 .
The average Applied Therapeutics, Inc. target price is $2.04.
This is
1,667.76%
register free of charge
$2.10
1,719.76%
register free of charge
$1.01
775.22%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Applied Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Applied Therapeutics, Inc. stock has an average upside potential 2026 of
1,667.76%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.46 | 1.02 |
| 95.40% | 121.74% | |
| EBITDA Margin | -22,580.43% | -9,439.00% |
| 3,414.78% | 58.20% | |
| Net Margin | -22,960.87% | -7,683.98% |
| 1,815.32% | 66.53% |
6 Analysts have issued a sales forecast Applied Therapeutics, Inc. 2025 . The average Applied Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Applied Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Applied Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.76 | -0.54 |
| 46.48% | 28.95% | |
| P/E | negative | |
| EV/Sales | 4.61 |
6 Analysts have issued a Applied Therapeutics, Inc. forecast for earnings per share. The average Applied Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Applied Therapeutics, Inc....
Current Applied Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 14 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| UBS |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| Baird |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Dec 23 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
UBS:
Locked
➜
Locked
|
Dec 02 2024 |
|
Locked
Baird:
Locked
➜
Locked
|
Nov 29 2024 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 29 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
